- Home
- APLM vs TENX Comparison
APLM vs TENX Comparison
Compare APLM & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- TENX
- Stock Information
- Founded
- APLM 2016
- TENX 1967
- Country
- APLM United States
- TENX United States
- Employees
- APLM N/A
- TENX N/A
- Industry
- APLM Blank Checks
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- TENX Health Care
- Exchange
- APLM Nasdaq
- TENX Nasdaq
- Market Cap
- APLM 15.6M
- TENX 19.5M
- IPO Year
- APLM N/A
- TENX N/A
- Fundamental
- Price
- APLM $9.75
- TENX $5.61
- Analyst Decision
- APLM Strong Buy
- TENX Strong Buy
- Analyst Count
- APLM 2
- TENX 4
- Target Price
- APLM $425.00
- TENX $20.67
- AVG Volume (30 Days)
- APLM 107.4K
- TENX 67.9K
- Earning Date
- APLM 02-15-2025
- TENX 11-13-2024
- Dividend Yield
- APLM N/A
- TENX N/A
- EPS Growth
- APLM N/A
- TENX N/A
- EPS
- APLM N/A
- TENX N/A
- Revenue
- APLM $2,101,000.00
- TENX N/A
- Revenue This Year
- APLM N/A
- TENX N/A
- Revenue Next Year
- APLM N/A
- TENX N/A
- P/E Ratio
- APLM N/A
- TENX N/A
- Revenue Growth
- APLM 70.54
- TENX N/A
- 52 Week Low
- APLM $6.50
- TENX $2.77
- 52 Week High
- APLM $105.00
- TENX $27.36
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- TENX 54.30
- Support Level
- APLM $7.23
- TENX $5.70
- Resistance Level
- APLM $8.88
- TENX $6.01
- Average True Range (ATR)
- APLM 1.37
- TENX 0.47
- MACD
- APLM 0.21
- TENX -0.08
- Stochastic Oscillator
- APLM 57.91
- TENX 12.15
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.